We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $60.0 for SpringWorks Therapeutics, spanning the last ...

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.44 per share a year ago. These ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Springworks Therapeutics (SWTX – Research ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025. The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected to ...

In this article, we are going to take a look at where SpringWorks Therapeutics Inc. (NASDAQ:SWTX) stands against the other ...

(SWTX) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors. A solid price increase over a ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...